SEC Form 3 · accession 0001209191-19-000582
Nightstar Therapeutics plc · NITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott M Whitcup
Director
Period of report
Jan 1, 2019
Accepted (ET)
Jan 2, 2019 · 9:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001711675
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | holding | — | — | — | 31,341 | D | ||
| Ordinary SharesF1,F2 | holding | — | — | — | 30,410 | D | ||
| Ordinary SharesF1,F3 | holding | — | — | — | 12,817 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4,F1 | $12.27 | holding | — | — | — | — | Feb 27, 2028 | Ordinary Shares | 18,200 | — | D |
Explanation of responses
- F1The ordinary shares, nominal value GBP 0.01 per share, of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.
- F2Represent unvested restricted share awards granted on April 26, 2017. Shares shall vest on a pro rata quarterly basis through April 1, 2021.
- F3Represent unvested restricted share awards granted on August 23, 2017. Shares shall vest on a pro rata quarterly basis through July 1, 2021.
- F4This option vests in full on the close of business a day before the Annual General Meeting of Shareholders.
Remarks
Exhibit List: Exhibit 24.1 - Power of Attorney